Latest news

Belgian scale-up Oncomfort raises €10 million in Series A funding co-led by Debiopharm and Crédit Mutuel Innovation to further develop…

Debiopharm’s New Generation Radionuclide Therapy Advances Into Clinical Research In The Fight Against Lung Cancer

Debiopharm’s IAP Antagonist Significantly Improves Overall Survival of High-Risk Head & Neck Cancer Patients

Nucleai Secured $6.5m Series-A Initial Closing Led by Debiopharm to Advance Ai-Powered Precision Oncology Platform

Debiopharm’s novel microbiome remodeling program licensed to Takeda for the treatment of gastrointestinal disorders

Debiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar® for Prostate Cancer

Acquisition of Debiopharm’s Investment Portfolio Company Kaiku Health Broadens Patient Access to Digital Oncology Intervention

Le Challenge pour la Qualité de vie du patient 2020 est maintenu et le délai de remise des projets prolongé…

Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy